Mucosal, ocular, and articular involvement; skin manifestations
NR
None
RTX 1 g every two weeks for two doses + PDN 0.5 mg/kg/day + MTX 15 mg/week
6 months
Improvement of ocular manifestations after 6 months. TADAI significant improvement on RTX. VA improved in two patients, remained unchanged in 1, and worsened in 7. Significant improvement of retinal, disc, and macular oedema in all patients